Related Articles
Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines
JF-305, a pancreatic cancer cell line is highly sensitive to the PARP inhibitor olaparib
PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports
Synergistic effects of olaparib combined with <em>ERCC1</em> on the sensitivity of cisplatin in non‑small cell lung cancer
PI3K p110α inhibition sensitizes cervical cancer cells with aberrant PI3K signaling activation to PARP inhibitor BMN673